Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of combination of zoledronic acid and organic selenium compound in the preparation of antitumor drugs

An anti-tumor drug, zoledronic acid technology, applied in the field of tumor treatment, can solve the problems of tumor cell apoptosis, DNA damage, cell cycle arrest, etc., and achieve the effect of efficiently inducing apoptosis

Active Publication Date: 2021-12-07
JINAN UNIVERSITY
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The results of the study showed that selenodiazole derivatives can inhibit the activity of TrxR in tumor cells, affect the clearance of ROS, and cause them to accumulate rapidly in tumor cells, resulting in DNA damage, cell cycle arrest, and finally induction of tumor cell apoptosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of zoledronic acid and organic selenium compound in the preparation of antitumor drugs
  • Application of combination of zoledronic acid and organic selenium compound in the preparation of antitumor drugs
  • Application of combination of zoledronic acid and organic selenium compound in the preparation of antitumor drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Study on anti-prostate tumor activity in vitro of ZOL and organic selenium compounds

[0037] In this experiment, we studied the in vitro antitumor activity of organic selenium compounds and ZOL on prostate cancer PC-3 cells. We look forward to the development of novel synergistic chemotherapy strategies for the treatment of tumors.

[0038] (1) Prostate cancer cells in logarithmic growth phase (PC-3 cells; purchased from American Type Culture Collection) were taken at a density of 2×10 4 cells / mL were seeded in 96-well plates (100 μL / well) and allowed to grow for 2 hours. PC-3 cells were pretreated with 20 μM ZOL for 8 h, and then 2 μM organic selenium compounds SeC and SeD (100 μL) were added to a 96-well plate, and no addition of ZOL and organic selenium compounds was used as a blank control, and the incubation was continued for 64 hours. After the time was up, 25 μL of MTT solution (5 mg / mL, PBS buffer) was added to each well and incubated for 4 hours. ...

Embodiment 2

[0055] Example 2 Study on the Effects of ZOL and Organoselenium Compounds on ROS Levels of Prostate Tumors

[0056] The excessive accumulation of reactive oxygen species ROS in cells is an important initial signal to cause cell damage, so we detected the effect of ZOL combined with organic selenium compounds (SeC, SeD) on prostate cancer cells after staining with DHE probes. Impact. The specific method is as follows:

[0057] The cells were inoculated in a 96-well plate at a density of 200,000 cells / mL. After the cells adhered to the wall for 24 hours (the medium used for culturing cells was DMEM medium), 50 μL of 20 μM ZOL was added to incubate for 2 to 8 hours as required. Afterwards, the DMEM medium was replaced with 20 μM, 100 μL DHE probe per well, incubated in the dark for 30 min, and SeC and SeD were added after ZOL incubation according to the requirements of each group (the concentration of SeC and SeD can be 0.25-8 μM; this paper The concentration of SeC and SeD use...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the combined use of zoledronic acid and an organic selenium compound in the preparation of antitumor drugs. In the in vitro cell experiment of the present invention, it is found that the inhibitory effect of a single organic selenium compound and a single zoledronic acid on tumor cells is obviously inferior to that of combined drugs, indicating that the combination of the two can form a synergistic effect, that is, the organic selenium compound and zoledronic acid can be used The synergistic effect of acid achieves the purpose of efficiently inducing tumor cell apoptosis. In the present invention, it is also found that the potential mechanism of zoledronic acid enhancing organoselenium compounds to inhibit the growth of prostate cancer cells is caused by inducing cells to produce excessive ROS. Therefore, zoledronic acid and organic selenium compounds can be used in combination to prepare antitumor drugs, or zoledronic acid can be used as a sensitizer of organic selenium compounds in the field of tumor treatment.

Description

technical field [0001] The invention relates to the technical field of tumor treatment, in particular to the combined use of zoledronic acid and an organic selenium compound in the preparation of antitumor drugs. Background technique [0002] Prostate cancer is one of the common malignant tumors of the male genitourinary system, and the incidence rate is increasing year by year and tends to be younger. Because the onset of prostate cancer is hidden, its symptoms are often ignored. When it is diagnosed, about 65% to 75% have already There is bone metastases. Prostate cancer bone metastasis will cause a series of bone-related diseases, including pathological fractures, spinal cord compression, malignant tumor hypercalcemia, etc. Bone pain is the most common symptom of advanced prostate cancer, which seriously affects the quality of life of patients. Therefore, how to improve the treatment effect while relieving the patient's pain and ensuring the quality of life of the patien...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/675A61K31/198A61K31/4184A61P35/00A61P13/08
Inventor 赵建夫陈填烽贺利贞段琳琪安玉琳
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com